摘要
用酶联法、同位素掺入法、同位素释放法等检测肿瘤病人血清ｓＩＬ－２Ｒ、ＴＮＦ、ＮＫ细胞活性、ＬＡＫ细胞活性、淋巴细胞转化及淋巴细胞对ＩＬ－２的反应性等免疫功能。结果表明：肿瘤病人血清ｓＩＬ－２Ｒ（２４１．９±１７２．５ｐｍｏｌ／Ｌ）及ＴＮＦ（１．８６±１．５２ｎｇ／ｍｌ）含量均显著高于健康对照组（分别为：１３４．２±７６．５ｐｍｏｌ／Ｌ，Ｐ＜０．０５～０．００５，０．６３±０．２０ｎｇ／ｍｌ）；而肿瘤病人ＮＫ细胞活性（１１．１８±６．９８）、ＬＡＫ细胞活性（１７．８６±９．５７）、淋巴细胞转化（３２．８３±５２．５９）及淋巴细胞对ＩＬ－２的反应性（５．９４±９．３１）等均显著低于健康对照组（分别为：２０．３３±１０．９７，３８．４９±８．１０，７５．７０±５２．６５和２４．５９±２８．２５，Ｐ＜０．０４～０．００１）。结果提示：肿瘤病人存在着多种免疫功能的改变，故应给予合理的过继免疫治疗。
Abstract To evaluate efficiency of LAK cells from patients with cancer a number of
immue functions ofpatients with advanced carcinoma was investigated. The results showed
that:from patients with cancer,lymphocyte transformation (32.83 ± 52.59),responses of
lymphocytes to IL-2(5.94± 9.31),and toIL-2/PHA(32.25 ± 43.05), and NK activity 11.18 ± 6.98),
LAK activity(17.86 ± 9.57) weresignificantly suppressed (In the healthy donors, the data were
75.70 ± 52.65, 24.59 ± 28.25, 125.47±74.11 respectively, P<0.001) , sIL-2R and TNF
concentrations(241.9±172.5pmol/L and 1.86±1.52ng/ml respectively)in serum from patients
with cancer were significantly higher than that ofhealthy control (134.2 ± 73.5pmol/L and 0.63
± 0.20ng/ml respectively, P<0.05～0.001).Since patients with cancer had suppressed
responses of lymphocytes to IL-2,low NK andLAK cell activity, LAK cells from patients with
cancer might be less effective than those from healthy donor in the treatment of cancer.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
1994年第6期415-418,共4页
Chinese Journal of Oncology
